Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.
The effects of interferon are seen in only a limited number of patients with hepatitis C virus (HCV) of the K1 type, indicating that a combination therapy with other antiviral drugs may be essential to obtain better results. In the present pilot study, the effects of combination therapy with interferon (IFN) and an antiviral drug azidothymidine (AZT) were analyzed. The combination therapy was conducted in 22 patients with chronic hepatitis C after obtaining their informed consent (combination group). Three or six million units of natural IFN alpha was administered daily for 3 weeks and then three times a week for 21 weeks. Combination therapy was initiated at the beginning of the 8th week of IFN treatment, 500 mg of AZT per day being given for 8 weeks. As a control, changes in HCV-RNA were also analyzed in patients treated with interferon alone (IFN-alone group). At the end of the treatment, blood was negative for HCV in 32.5% of the IFN-alone group and in 50.0% of the combination group, the difference not being significant. However, in patients with HCV-K1, HCV-negative rates were 14.2% in the IFN-alone group and 45.5% in the combination group, showing a significant difference. In patients with other HCV genotypes, HCV-negative rates did not different between the two groups. These results suggest that combination therapy with IFN and AZT may be an effective treatment for chronic type C hepatitis caused by the K1 type virus, although further studies on larger number of patients will be needed to obtain definite conclusions.